Ferric Citrate API: A Phosphate Binder Sourcing Guide

Hyperphosphatemia affects the majority of patients with advanced chronic kidney disease worldwide. Generic manufacturers targeting this therapeutic segment need a reliable, well-characterised API. Phosphate binder ferric citrate offers a clinically distinct advantage over older binders. It controls serum phosphorus while simultaneously addressing iron deficiency, a dual action no competing class delivers.

This guide is written for B2B procurement teams, formulation scientists, and regulatory affairs professionals evaluating ferric citrate API sourcing. It covers clinical positioning, comparative binder analysis, tablet manufacturing specifications, regulatory documentation requirements, and supplier qualification.

Key Takeaways:

• Each 1g ferric citrate tablet delivers exactly 210 mg of elemental ferric iron, a specification your API must reliably meet batch to batch.
• Ferric citrate achieves equivalent phosphorus control to sevelamer carbonate while reducing IV iron use and ESA dependency in dialysis patients.
• Regulatory sourcing for ANDA filing requires Mössbauer spectroscopy, XRPD, and comparative testing against a minimum of three RLD batches.
• WHO-GMP-certified Indian API suppliers with filed USDMFs are well-positioned to serve global generic formulation programmes cost-competitively.

Quick Answer: Ferric citrate is the only FDA-approved iron-based phosphate binder with a simultaneous iron deficiency anaemia indication in CKD patients.

What Is the Clinical Role of Ferric Citrate as a Phosphate Binder in CKD?

Phosphate binder ferric citrate works through a straightforward ionic interaction in the gastrointestinal tract. Fe³⁺ ions from ferric citrate bind dietary phosphate after oral ingestion with meals. This forms insoluble ferric phosphate complexes that the body cannot absorb. The complexes are excreted entirely in stool, preventing phosphate entry into systemic circulation. Serum phosphorus levels fall as a direct result of reduced intestinal absorption. This mechanism requires the API to maintain ferric iron in the trivalent oxidation state. Any reduction to Fe²⁺ compromises binding efficiency and clinical performance. Formulators must therefore specify oxidation state verification as a mandatory CoA parameter.
The US FDA approved ferric citrate in 2014 for controlling serum phosphorus in dialysis-dependent CKD patients [1]. A second indication was subsequently approved for treating iron deficiency anaemia in non-dialysis CKD patients. KDIGO guidelines recommend maintaining serum phosphorus below 5.5 mg/dL in dialysis patients. Phosphate binder ferric citrate is now an accepted first-line iron-based option within these guidelines. Understanding this dual regulatory purpose is critical before designing your formulation strategy.

Ferric Citrate vs. Calcium-Based and Sevelamer Phosphate Binders

Generic formulators entering this market must understand where phosphate binder ferric citrate sits competitively.

Three main phosphate binder classes currently dominate clinical use:

A 2022 meta-analysis covering 16 randomised controlled trials and 1,754 participants confirmed that iron-based phosphate binders perform equivalently to sevelamer and calcium-based active controls on serum phosphorus reduction [2]. The key differentiator is the haemoglobin improvement that ferric citrate uniquely provides.

Dual-Indication Manufacturing: Formulating Ferric Citrate Tablets for Both Phosphate Binding and Iron Deficiency Anaemia

Ferric citrate API supports two distinct label claims depending on the patient population being targeted. Formulators must decide upfront which indication, or both, their generic product will carry.

• Dialysis-dependent CKD (Hyperphosphatemia): Tablets taken with every meal to bind dietary phosphate continuously throughout the day.
• Non-dialysis CKD (Iron Deficiency Anaemia): Iron absorbed from the ferric citrate matrix replenishes systemic iron stores gradually over weeks.

The same API specification supports both pathways. However, clinical outcomes documentation and bioequivalence strategy differ for each regulatory submission.

Tablet Specification and API Requirements

The reference listed drug Auryxia contains 1g of ferric citrate per tablet, delivering 210 mg of elemental ferric iron. This specification drives the following API requirements:

• Assay: Elemental iron content must be confirmed by atomic absorption spectroscopy or ICP.
• Oxidation state: Fe³⁺ (ferric) must be verified; Fe²⁺ contamination impairs phosphate binding.
• Particle size: Influences dissolution rate and phosphate-binding kinetics in the GI tract.
• Heavy metals: Citrate increases aluminium absorption risk; lead and aluminium limits must be tightly controlled.
• Moisture content: Affects powder flow and compressibility during tablet manufacturing.

Iron Deficiency Outcomes

In non-dialysis CKD patients, ferric citrate safely increases mean haemoglobin by 0.8-1.3 g/dL over 16 weeks of treatment [3]. This figure comes from Phase 3 clinical data and is the benchmark your formulation must replicate bioequivalently.

Regulatory Documentation Requirements for Ferric Citrate API

Sourcing phosphate binder ferric citrate for regulated markets requires a specific set of technical and regulatory documents. Missing even one can significantly delay an ANDA or MAA filing. The following documentation is non-negotiable when qualifying a ferric citrate API supplier.

Drug Master File (DMF)

USDMF (Type II) for US ANDA filings; ASMF/EDMF for EU MAA submissions. Must include full manufacturing process, impurity profile, and stability data. Cross-reference authorisation letter must be provided to the formulator.

Certificate of Analysis (CoA)

Critical documents include assay (elemental iron %), oxidation state, related substances, heavy metals, moisture, particle size distribution. FDA Product-Specific Guidance for ferric citrate specifically requires Mössbauer spectroscopy and X-ray powder diffraction (XRPD) data in the API characterisation package.

Comparative API Characterisation

A minimum of three batches of test API must be characterised side-by-side against three batches extracted from the RLD (Auryxia). High-resolution mass spectroscopy (HRMS) and ferric iron-to-citrate ratio data must be documented.

Good Manufacturing Practice Certification

WHO-GMP certificate is the minimum for most regulated markets, including India, ASEAN, and parts of Africa. US FDA site inspection or an EU GMP compliance certificate is required for USFDA and EMA market access.

Written Confirmation (WC)

Required by the European Medicines Agency for API exports from non-EU countries, including India.

How to Qualify a Ferric Citrate API Supplier

Supplier qualification for phosphate binder ferric citrate is a multi-step process. Skipping steps creates downstream risk during ANDA review or batch-release audits.

Regulatory credentials verify before requesting samples:

• WHO-GMP certificate (current, not expired) covering the ferric citrate API manufacturing site.
• USDMF filed with FDA; confirm DMF number and cross-reference authorisation is available.
• Written Confirmation for EU markets if targeting EMA-regulated geographies.
• CEP/COS from EDQM for European Pharmacopoeia compliance.

Technical documentation request with first sample batch:

• Full CoA with elemental iron %, oxidation state confirmation, XRPD and Mössbauer data.
• ICH Q1A-compliant stability data covering 24-month long-term and 6-month accelerated conditions.
• Batch-to-batch consistency data across a minimum of three commercial batches.

Operational factors assessed during supplier audit:

• Demonstrated scale-up capability from clinical to commercial batch sizes.
• Safety-stock inventory policy to protect against supply disruption.
• Dedicated ferric iron production lines to prevent cross-contamination with ferrous salts.

Why India Is a Strategic Sourcing Hub

Indian API manufacturers, including West Bengal Chemical Industries (WBCIL), combine WHO-GMP compliance with full regulatory dossier support. WBCIL provides ferric citrate API with complete documentation covering USDMF cross-references, CoA, stability data, and regulatory support for FSSAI, US, and EU submissions. This makes Indian-sourced ferric citrate API cost-competitive without sacrificing the regulatory rigour that ANDA filers require.

Final Thoughts

Phosphate binder ferric citrate occupies a clinically and commercially unique position in the CKD treatment landscape. No other oral phosphate binder simultaneously addresses hyperphosphatemia and iron deficiency anaemia within a single approved tablet. For Indian generic manufacturers, this represents a formulation opportunity with a clear regulatory pathway and a growing global patient base. The sourcing decision, however, is entirely on API quality. Suppliers must provide complete spectroscopic characterisation, a filed DMF, and credible batch consistency data. West Bengal Chemical Industries ferric citrate documentation meets these requirements, offering a reliable entry point for manufacturers targeting both US and EU generic markets.